Bridgebio Pharma Inc 's ability to collect accounts receivable sequentially worsen to 3.88, indicating more challenging environment then in the second quarter 2026, but still, it is a far cry from any concerns. Bridgebio Pharma Inc 's Accounts Receivable average collection period in the Sep 30 2026 quarter, has increased to 94 days, from 91 days, in the Jun 30 2026 quarter.

If we take a look into Healthcare sector 222 other companies have achieved higher receivables turnover ratio. While receivables turnover ratio total ranking has improved thus far to 1899, from overall ranking in the second quarter 2026 at 2816.

What is Receivable Turnover Ratio?
What is Bridgebio Pharma Inc Selling?

What is Receivable Turnover Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Accounts Receivables Turnover▼

None ▼

Accounts Receivables Turnover▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

BBIO Receivables Turnover Ratio	(Sep 30 2026) III. Quarter	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter
Y / Y Receivable Change	221.92 %	231.07 %	78.05 %	2853.07 %	24276.15 %
Y / Y Revenue Change	192.6 %	120.39 %	66.78 %	2521.18 %	4318.01 %
Receivable Turnover Ratio (TTM)	3.88	3.99	4.31	4.48	4.52
BBIO's Total Ranking	# 1899	# 2816	# 1832	# 2275	#
Accounts Receivable average collection period days	94	92	85	81	81
Seq. Receivable Change	47.39 %	24 %	47.17 %	19.68 %	51.58 %
Seq. Revenue Change	44.93 %	25.27 %	26.16 %	27.74 %	9.17 %

Receivable Turnover Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 57
Healthcare Sector	# 223
Overall Market	# 1899

Receivable Turnover Ratio Statistics
High	Average	Low
0.63	0.21	0.01
(Jun 30 2026)		(Jun 30 2023)

BBIO Company Profile • Back to BBIO Efficiency Comparisons • Compare BBIO Receivables Turnover Ratio to its Competitors

Financial Statements
Bridgebio Pharma Inc 's Accounts Receivable	$ 375 Millions	Visit BBIO's Balance sheet
Bridgebio Pharma Inc 's Sales TTM	$ 946 Millions	Visit BBIO's Income Statement
Sources of BBIO's Revenues		Visit BBIO's Sales by Geography

Other Accounts Receivable Turnover Ratios
Major Pharmaceutical Preparations Industry Accounts Receivable Turnover Trends and Statistics
Healthcare Sector Accounts Receivable Turnover Statistics
Accounts Receivables Turnover Trends for overall market
BBIO's Receivable Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Accounts Receivables Turnover
Lowest Ranking Accounts Receivables Turnover

You may also want to know
BBIO's Growth Rates	BBIO's Roa	BBIO's Inventory Turnover Ratio	BBIO's Dividend Comparisons
BBIO's Profitability Ratios	BBIO's Roi	BBIO's Asset Turnover Ratio	BBIO's Dividend Growth
BBIO's Valuation Ratios	BBIO's Roe	BBIO's Financial Strength Ratios	BBIO's Dividend Payout Ratio

Companies with similar Receivables Turnover Ratio for the quarter ending Sep 30 2026, within Healthcare Sector	Receivable Turnover Ratio	Revenues for 12 Months ending Sep 30 2026	Receivable at quarter ending Sep 30 2026
Syndax Pharmaceuticals Inc	6.89	$ 289.431 Millions	$ 42.011 Millions
Hca Healthcare Inc	6.85	$ 78,701.000 Millions	$ 11,495.250 Millions
Ceribell Inc	6.77	$ 109.203 Millions	$ 16.138 Millions
Medpace Holdings Inc	6.73	$ 2,838.385 Millions	$ 421.525 Millions
Carlisle Companies Incorporated	6.67	$ 5,213.500 Millions	$ 781.625 Millions
Iradimed Corporation	6.62	$ 89.340 Millions	$ 13.487 Millions
3m Company	6.59	$ 25,247.000 Millions	$ 3,832.500 Millions
Baxter International Inc	6.55	$ 11,784.000 Millions	$ 1,799.500 Millions
Haemonetics Corporation	6.48	$ 1,382.737 Millions	$ 213.396 Millions
Zevra Therapeutics Inc	6.40	$ 140.548 Millions	$ 21.947 Millions
Bruker Corporation	6.39	$ 3,512.500 Millions	$ 549.350 Millions
Labcorp Holdings Inc	6.38	$ 14,594.500 Millions	$ 2,286.925 Millions
Healthcare Services Group Inc	6.36	$ 1,879.860 Millions	$ 295.784 Millions
Intellia Therapeutics Inc	6.33	$ 52.887 Millions	$ 8.355 Millions
Gilead Sciences Inc	6.29	$ 30,988.000 Millions	$ 4,929.000 Millions
Integra Lifesciences Holdings Corp	6.26	$ 1,656.786 Millions	$ 264.861 Millions
Neogen Corporation	6.17	$ 884.120 Millions	$ 143.371 Millions
Vertex Pharmaceuticals Inc	6.10	$ 12,951.600 Millions	$ 2,123.550 Millions
Mimedx Group Inc	6.06	$ 303.363 Millions	$ 50.077 Millions
Rxsight Inc	6.00	$ 122.088 Millions	$ 20.336 Millions
Avantor Inc	5.98	$ 6,635.600 Millions	$ 1,110.300 Millions
Msa Safety Inc	5.96	$ 2,015.730 Millions	$ 338.388 Millions
Bio rad Laboratories Inc	5.92	$ 2,593.000 Millions	$ 437.800 Millions
Illumina Inc	5.87	$ 4,538.000 Millions	$ 773.500 Millions
Resmed Inc	5.82	$ 5,743.164 Millions	$ 986.765 Millions
Conmed Corporation	5.76	$ 1,369.288 Millions	$ 237.544 Millions
Clearpoint Neuro Inc	5.75	$ 45.493 Millions	$ 7.906 Millions
Davita Inc	5.75	$ 14,167.545 Millions	$ 2,462.529 Millions
Strata Critical Medical Inc	5.71	$ 236.425 Millions	$ 41.435 Millions
Standard Biotools Inc	5.69	$ 83.592 Millions	$ 14.699 Millions

Date modified: 2026-10-30T17:01:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.